Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 14 | 2024 | 67 | 6.790 |
Why?
|
| Laser Coagulation | 7 | 2021 | 54 | 2.450 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2023 | 315 | 2.250 |
Why?
|
| Bevacizumab | 8 | 2023 | 287 | 2.010 |
Why?
|
| Endophthalmitis | 2 | 2023 | 22 | 1.750 |
Why?
|
| Cataract Extraction | 2 | 2023 | 33 | 1.750 |
Why?
|
| Infant, Newborn | 17 | 2024 | 2464 | 1.270 |
Why?
|
| Cataract | 2 | 2023 | 86 | 1.230 |
Why?
|
| Gestational Age | 9 | 2024 | 323 | 1.000 |
Why?
|
| Infant, Premature, Diseases | 2 | 2021 | 77 | 0.920 |
Why?
|
| Aphakia | 1 | 2023 | 10 | 0.870 |
Why?
|
| Intravitreal Injections | 6 | 2023 | 69 | 0.870 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 42 | 0.850 |
Why?
|
| Lens, Crystalline | 1 | 2023 | 69 | 0.820 |
Why?
|
| Developmental Disabilities | 1 | 2023 | 202 | 0.800 |
Why?
|
| Infant, Premature | 6 | 2024 | 295 | 0.790 |
Why?
|
| Databases, Factual | 1 | 2023 | 849 | 0.690 |
Why?
|
| Infant | 9 | 2024 | 3130 | 0.680 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 501 | 0.650 |
Why?
|
| Myopia | 2 | 2017 | 10 | 0.600 |
Why?
|
| Retrospective Studies | 10 | 2024 | 8960 | 0.570 |
Why?
|
| Postoperative Complications | 2 | 2023 | 2273 | 0.540 |
Why?
|
| Ophthalmology | 1 | 2016 | 43 | 0.520 |
Why?
|
| Tomography, Optical Coherence | 7 | 2024 | 135 | 0.470 |
Why?
|
| Humans | 32 | 2024 | 88835 | 0.440 |
Why?
|
| Choroid | 2 | 2024 | 35 | 0.430 |
Why?
|
| Communication | 1 | 2016 | 457 | 0.410 |
Why?
|
| Child | 7 | 2023 | 7112 | 0.410 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 390 | 0.400 |
Why?
|
| Proteomics | 1 | 2023 | 230 | 0.390 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 625 | 0.370 |
Why?
|
| Retinal Detachment | 2 | 2021 | 66 | 0.360 |
Why?
|
| Child, Preschool | 3 | 2023 | 3695 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2023 | 420 | 0.340 |
Why?
|
| Incidence | 2 | 2023 | 1591 | 0.320 |
Why?
|
| Physicians | 1 | 2016 | 689 | 0.320 |
Why?
|
| Retinal Vessels | 3 | 2024 | 59 | 0.310 |
Why?
|
| Fluorescein Angiography | 4 | 2023 | 96 | 0.300 |
Why?
|
| Scleritis | 1 | 2016 | 5 | 0.290 |
Why?
|
| Sclera | 1 | 2016 | 11 | 0.290 |
Why?
|
| Founder Effect | 1 | 2017 | 104 | 0.280 |
Why?
|
| Streptococcal Infections | 1 | 2016 | 56 | 0.280 |
Why?
|
| Internship and Residency | 1 | 2016 | 1040 | 0.280 |
Why?
|
| Risk Factors | 3 | 2023 | 5447 | 0.250 |
Why?
|
| Retinal Perforations | 1 | 2024 | 19 | 0.230 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 69 | 0.220 |
Why?
|
| Mobile Applications | 1 | 2024 | 68 | 0.210 |
Why?
|
| Parturition | 1 | 2022 | 21 | 0.210 |
Why?
|
| Diabetic Retinopathy | 1 | 2024 | 91 | 0.210 |
Why?
|
| Smartphone | 1 | 2023 | 39 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2023 | 159 | 0.210 |
Why?
|
| Female | 13 | 2024 | 45893 | 0.210 |
Why?
|
| Child Development | 1 | 2024 | 166 | 0.200 |
Why?
|
| Male | 12 | 2024 | 42127 | 0.200 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2021 | 8 | 0.200 |
Why?
|
| Fovea Centralis | 1 | 2021 | 21 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2024 | 778 | 0.200 |
Why?
|
| Mucolipidoses | 1 | 2021 | 3 | 0.190 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 69 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 320 | 0.190 |
Why?
|
| Movement | 1 | 2022 | 307 | 0.180 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.170 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 9 | 0.170 |
Why?
|
| Refraction, Ocular | 1 | 2019 | 9 | 0.170 |
Why?
|
| Vitreous Hemorrhage | 1 | 2018 | 11 | 0.160 |
Why?
|
| Hearing Loss | 1 | 2019 | 59 | 0.160 |
Why?
|
| Vitreous Body | 1 | 2018 | 54 | 0.160 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 96 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 1835 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1698 | 0.150 |
Why?
|
| Keratoconus | 1 | 2017 | 11 | 0.150 |
Why?
|
| Cornea | 1 | 2017 | 70 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2019 | 684 | 0.150 |
Why?
|
| Hypertension | 1 | 2023 | 741 | 0.140 |
Why?
|
| Adolescent | 3 | 2023 | 9201 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 738 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2024 | 4255 | 0.110 |
Why?
|
| Aqueous Humor | 1 | 2023 | 24 | 0.110 |
Why?
|
| Syndrome | 2 | 2021 | 449 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 193 | 0.100 |
Why?
|
| Video Recording | 2 | 2024 | 201 | 0.100 |
Why?
|
| Fundus Oculi | 2 | 2023 | 33 | 0.100 |
Why?
|
| United States | 1 | 2023 | 6928 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 780 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2023 | 456 | 0.090 |
Why?
|
| Time Factors | 1 | 2019 | 5311 | 0.090 |
Why?
|
| Adult | 5 | 2023 | 26437 | 0.090 |
Why?
|
| Fluoresceins | 1 | 2018 | 43 | 0.080 |
Why?
|
| Axial Length, Eye | 1 | 2017 | 1 | 0.070 |
Why?
|
| Retinoscopy | 1 | 2017 | 2 | 0.070 |
Why?
|
| Zinc | 1 | 2008 | 93 | 0.070 |
Why?
|
| South Dakota | 1 | 2017 | 47 | 0.070 |
Why?
|
| Visual Acuity | 2 | 2018 | 197 | 0.070 |
Why?
|
| Biometry | 1 | 2017 | 66 | 0.070 |
Why?
|
| Anterior Eye Segment | 1 | 2016 | 6 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2008 | 134 | 0.070 |
Why?
|
| Biomarkers | 1 | 2023 | 1751 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 243 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 428 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 275 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 668 | 0.060 |
Why?
|
| Ophthalmoscopy | 1 | 2024 | 13 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2016 | 710 | 0.060 |
Why?
|
| Vitrectomy | 1 | 2024 | 52 | 0.060 |
Why?
|
| Motor Skills | 1 | 2024 | 79 | 0.060 |
Why?
|
| Morbidity | 1 | 2023 | 149 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1590 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 782 | 0.050 |
Why?
|
| Retina | 1 | 2024 | 216 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 778 | 0.050 |
Why?
|
| Arthritis | 1 | 2021 | 47 | 0.050 |
Why?
|
| Lasers | 1 | 2021 | 107 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3649 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 47 | 0.050 |
Why?
|
| Capillaries | 1 | 2021 | 90 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 198 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2021 | 45 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 145 | 0.050 |
Why?
|
| Parents | 1 | 2024 | 285 | 0.050 |
Why?
|
| Chicago | 1 | 2024 | 1423 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 6271 | 0.040 |
Why?
|
| Corneal Topography | 1 | 2017 | 10 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 2750 | 0.040 |
Why?
|
| Aged | 2 | 2021 | 19014 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6757 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1870 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3002 | 0.030 |
Why?
|
| Middle Aged | 2 | 2021 | 25783 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2024 | 8177 | 0.020 |
Why?
|
| Oxacillin | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 2008 | 39 | 0.020 |
Why?
|
| Solutions | 1 | 2008 | 85 | 0.020 |
Why?
|
| Phospholipids | 1 | 2008 | 111 | 0.020 |
Why?
|
| Vancomycin | 1 | 2008 | 73 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 75 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 168 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 385 | 0.020 |
Why?
|
| Water | 1 | 2008 | 283 | 0.020 |
Why?
|